Clinical stage Australian company OncoSil Medical's (ASX:OSL)...

Clinical stage Australian company OncoSil Medical's (ASX:OSL) director Lawrence Gozlan has stepped down from the board of OncoSil Medical, effective from today.

Gozlan joined the board in February 2014 and will now focus on his other business interests.

OncoSil Medical chairman Dr Roger Aston said:

“Lawrence has been a key member of the OncoSil Medical team. His drive and enthusiasm along with his undoubted knowledge and understanding of the listed life sciences space has been of major benefit to the Company.

"He has a growing portfolio of business interests which require his commitment and time, and we acknowledge his decision to step down in order to focus on these interests.”

OncoSil is a clinical-stage Australian lifesciences company focused on providing new technologies for safer medical radiation treatments.

OncoSil Medical’s lead product is OncoSil™ with the first target indication being pancreatic & hepatocellular cancer.

The has been awarded ISO 13485:2012 and ISO 13485:2003 certification for the design, development and control of manufacture of its radioactive implantable medical device in the area of oncology.

The certification is a key requirement for CE Marking of Medical Devices in the European Union.

OncoSil now plans to secure CE Mark in both pancreatic and liver cancer indications in the September quarter, 2015.

Under the leadership of new CEO Daniel Kenny, OncoSil has conducted a detailed strategic clinical and regulatory review of the OncoSil device program.

As a result the company has determined to aggressively pursue a global registration program in both pancreatic and hepatocellular (primary liver cancer) cancer.

Upcoming price catalysts include the final design of a Pivotal Study for Pancreatic cancer protocol by end of Q2 2015.

The first patients would be recruited for the Pivotal Study by end of Q3 2015.

While the the CE Mark approval is likely by the end Q3 2015 and the IDE approval by Q4 2015.